Meeting at the Cellular Interface: CAR-T Cell Versus B cell Cancers

Meeting at the Cellular Interface: CAR-T Cell Versus B cell Cancers

Collections: Now On Display, Image Award Winners

2024 Award Winner

Keith P. Eidell, Aslı Gökdemir, Michael T. Hemann

Koch Institute at MIT

Chimeric Antigen Receptor (CAR)  T cell immunotherapy has revolutionized how we treat blood cancers such as B cell leukemias. While this new therapy can be highly effective, cancers often recur.

To understand mechanisms of treatment failure, Hemann Lab researchers are investigating the dynamic interactions between CAR-T cells and B cell malignancies, using microscopy to gain insight into how cancer cells evade or succumb to CAR-T therapy. Here a CAR-T cell (green) attaches to and destroys a leukemia cell (red). 

A comma-shaped swirl of magenta spheroids punctuated with a large green spheroid at the top

Video

More like this